Artemis Medicare Services And 2 Other Companies That Investors Might Be Undervaluing On The Indian Exchange

The Indian market has experienced a flat performance over the past week, yet it has shown impressive growth of 40% in the last year, with earnings expected to increase by 17% annually in the coming years. In such an environment, identifying undervalued stocks like Artemis Medicare Services can be crucial for investors seeking opportunities that may offer potential value relative to their current market price.

Top 10 Undervalued Stocks Based On Cash Flows In India

Name	Current Price	Fair Value (Est)	Discount (Est)
Titagarh Rail Systems (NSEI:TITAGARH)	₹1146.60	₹2143.76	46.5%
RITES (NSEI:RITES)	₹307.30	₹516.66	40.5%
IOL Chemicals and Pharmaceuticals (BSE:524164)	₹433.20	₹762.32	43.2%
Vedanta (NSEI:VEDL)	₹489.85	₹902.35	45.7%
Patel Engineering (BSE:531120)	₹54.59	₹91.76	40.5%
Orchid Pharma (NSEI:ORCHPHARMA)	₹1363.70	₹2142.32	36.3%
Artemis Medicare Services (NSEI:ARTEMISMED)	₹282.25	₹445.15	36.6%
Tarsons Products (NSEI:TARSONS)	₹414.25	₹706.73	41.4%
Manorama Industries (BSE:541974)	₹917.15	₹1665.51	44.9%
Strides Pharma Science (NSEI:STAR)	₹1565.95	₹2704.30	42.1%

Click here to see the full list of 26 stocks from our Undervalued Indian Stocks Based On Cash Flows screener.

Below we spotlight a couple of our favorites from our exclusive screener.

Artemis Medicare Services (NSEI:ARTEMISMED)

Overview: Artemis Medicare Services Limited operates and manages multi-specialty hospitals in India and internationally, with a market cap of ₹38.84 billion.

Operations: The company's revenue primarily comes from its healthcare services segment, which generated ₹8.92 billion.

Estimated Discount To Fair Value: 36.6%

Artemis Medicare Services is trading at ₹282.25, significantly below its estimated fair value of ₹445.15, indicating potential undervaluation based on cash flows. Despite a high debt level, the company shows strong earnings growth with a 40% increase over the past year and forecasts of 36.5% annual growth, outpacing the Indian market's average. Recent inclusion in the S&P Global BMI Index may enhance visibility and investor interest in this undervalued stock.

• Our comprehensive growth report raises the possibility that Artemis Medicare Services is poised for substantial financial growth.
• Take a closer look at Artemis Medicare Services' balance sheet health here in our report.

Strides Pharma Science (NSEI:STAR)

Overview: Strides Pharma Science Limited develops, manufactures, and sells pharmaceutical products across Africa, Australia, North America, Europe, Asia, India, and internationally with a market cap of ₹144 billion.

Operations: The company's revenue primarily comes from its Pharmaceutical Business, excluding the Bio-Pharmaceutical segment, amounting to ₹42.09 billion.

Estimated Discount To Fair Value: 42.1%

Strides Pharma Science, trading at ₹1565.95, is considered undervalued with a fair value estimate of ₹2704.3 based on cash flows. The company has shown improved financial health by reducing its non-convertible debentures from ₹1,250 million to ₹242 million recently. Earnings are projected to grow significantly at 99.48% annually as the company aims for profitability within three years, surpassing average market growth expectations despite slower revenue growth compared to some peers.

• The growth report we've compiled suggests that Strides Pharma Science's future prospects could be on the up.
• Click to explore a detailed breakdown of our findings in Strides Pharma Science's balance sheet health report.

Titagarh Rail Systems (NSEI:TITAGARH)

Overview: Titagarh Rail Systems Limited manufactures and sells freight and passenger rail systems in India and internationally, with a market cap of ₹154.42 billion.

Operations: The company's revenue segments include Passenger Rail Systems generating ₹3.32 billion and Freight Rail Systems (including shipbuilding, bridges, and defense) contributing ₹35.14 billion.

Estimated Discount To Fair Value: 46.5%

Titagarh Rail Systems, priced at ₹1146.6, is trading significantly below its fair value estimate of ₹2143.76 based on cash flows. The company forecasts robust revenue and earnings growth rates of 25.7% and 30.1% annually, respectively, outpacing the broader Indian market's expectations. Recent developments include a revised wagon order valued at ₹71 billion with Indian Railways to optimize capacity and avoid penalties, reflecting strategic operational adjustments despite past shareholder dilution concerns.

• The analysis detailed in our Titagarh Rail Systems growth report hints at robust future financial performance.
• Dive into the specifics of Titagarh Rail Systems here with our thorough financial health report.

Key Takeaways

• Investigate our full lineup of 26 Undervalued Indian Stocks Based On Cash Flows right here.
• Are you invested in these stocks already? Keep abreast of every twist and turn by setting up a portfolio with Simply Wall St, where we make it simple for investors like you to stay informed and proactive.
• Streamline your investment strategy with Simply Wall St's app for free and benefit from extensive research on stocks across all corners of the world.

Ready To Venture Into Other Investment Styles?

• Explore high-performing small cap companies that haven't yet garnered significant analyst attention.
• Diversify your portfolio with solid dividend payers offering reliable income streams to weather potential market turbulence.
• Fuel your portfolio with companies showing strong growth potential, backed by optimistic outlooks both from analysts and management.

This article by Simply Wall St is general in nature. We provide commentary based on historical data and analyst forecasts only using an unbiased methodology and our articles are not intended to be financial advice. It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your financial situation. We aim to bring you long-term focused analysis driven by fundamental data. Note that our analysis may not factor in the latest price-sensitive company announcements or qualitative material. Simply Wall St has no position in any stocks mentioned.

Have feedback on this article? Concerned about the content? Get in touch with us directly. Alternatively, email editorial-team@simplywallst.com